Patents by Inventor Panliang GAO

Panliang GAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS G12D Inhibitors
    Publication number: 20240059710
    Abstract: KRAS G12D inhibitors of Formula (I), a composition containing the inhibitor and the use thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: February 22, 2024
    Inventors: Huifeng HAN, Panliang GAO, Wenlong ZHANG, Cunbo MA, Peng WANG, Dan LIU, Hao ZHANG, Wei LONG
  • KRAS G12D Inhibitors
    Publication number: 20240025918
    Abstract: Provided are KRAS G12D inhibitors of formula (I), a composition containing the inhibitors, a prodrug thereof, a PROTAC compound thereof and the use thereof.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 25, 2024
    Inventors: Huifeng HAN, Panliang GAO, Wenlong ZHANG, Cunbo MA, Peng WANG, Dan LIU, Hao ZHANG, Wei LONG
  • Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
    Publication number: 20210393623
    Abstract: The present invention provides a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, the present invention provides a pharmaceutical composition comprising the said compound.
    Type: Application
    Filed: September 26, 2019
    Publication date: December 23, 2021
    Inventors: Huifeng Han, Panliang Gao, Cunbo Ma, Di Kang
  • Heterocyclic derivatives useful as SHP2 inhibitors
    Patent number: 10988466
    Abstract: This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: April 27, 2021
    Assignee: Jacobio Pharmaceuticals Co., Ltd.
    Inventors: Cunbo Ma, Panliang Gao, Shaojing Hu, Zilong Xu, Huifeng Han, Xinping Wu, Di Kang
  • KRAS MUTANT PROTEIN INHIBITORS
    Publication number: 20210040089
    Abstract: The invention relates to a KRAS mutant protein inhibitor, as shown by formula (I), a composition containing the inhibitor and the use thereof.
    Type: Application
    Filed: August 6, 2020
    Publication date: February 11, 2021
    Inventors: Panliang GAO, Cunbo MA, Peng WANG, Dan LIU
  • NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS
    Publication number: 20200392128
    Abstract: This invention relates to certain novel pyrazine derivatives (Formula I) as SHP2 inhibitors which is shown as formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, this invention is directed to fused heterocyclic group derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.
    Type: Application
    Filed: March 23, 2018
    Publication date: December 17, 2020
    Inventors: Cunbo Ma, Panliang Gao, Shaojing Hu, Zilong Xu, Huifeng Han, Xinping Wu, Di Kang
  • Heterocyclic ring derivatives useful as SHP2 inhibitors
    Patent number: 10858359
    Abstract: Provided are certain novel pyrazine derivatives (I) as SHP2 inhibitors which is shown as formula (I), their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided are fused heterocyclic derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: December 8, 2020
    Assignee: JACOBIO PHARMACEUTICALS CO., LTD.
    Inventors: Cunbo Ma, Panliang Gao, Jie Chu, Xinping Wu, Chunwei Wen, Di Kang, Jinlong Bai, Xiaoyan Pei
  • NOVEL HETEROCYCLIC RING DERIVATIVES USEFUL AS SHP2 INHIBITORS
    Publication number: 20190127378
    Abstract: Provided are certain novel pyrazine derivatives (I) as SHP2 inhibitors which is shown as formula (I), their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided are fused heterocyclic derivatives useful as inhibitors of SHP2, methods for producing such compounds and methods for treating a SHP2-mediated disorder.
    Type: Application
    Filed: June 7, 2017
    Publication date: May 2, 2019
    Inventors: Cunbo MA, Panliang GAO, Jie CHU, Xinping WU, Chunwei WEN, Di KANG, Jinlong BAI, Xiaoyan PEI